HC Wainwright Has Bearish Outlook for ARWR FY2025 Earnings

Key Points

• HC Wainwright downgraded its earnings per share (EPS) estimate for Arrowhead Pharmaceuticals in FY2025 to ($0.20), significantly down from a previous estimate of $1.57.
• The company reported disappointing quarterly earnings, with an EPS of ($1.26) that missed the consensus estimate of ($0.94) by ($0.32), alongside revenues of $27.77 million.
• Despite a "Buy" rating from HC Wainwright and a price objective of $80.00, other analysts have offered mixed ratings, with the consensus target price now at $43.14.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($0.20) per share for the year, down from their prior estimate of $1.57. HC Wainwright has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at $0.17 EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($3.20) EPS and FY2029 earnings at ($1.32) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analysts' expectations of $29.01 million. During the same quarter in the prior year, the company posted ($1.38) earnings per share.

Other equities analysts have also recently issued research reports about the stock. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday. Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday. Royal Bank Of Canada lowered their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock traded up $0.40 during mid-day trading on Friday, hitting $19.18. 771,206 shares of the stock were exchanged, compared to its average volume of 1,912,630. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $27.34. The company has a 50-day simple moving average of $16.63 and a 200 day simple moving average of $15.94. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The company has a market capitalization of $2.65 billion, a P/E ratio of -14.98, a P/E/G ratio of 76.81 and a beta of 0.94.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARWR. Wells Fargo & Company MN grew its position in shares of Arrowhead Pharmaceuticals by 43.1% during the 4th quarter. Wells Fargo & Company MN now owns 62,886 shares of the biotechnology company's stock valued at $1,182,000 after purchasing an additional 18,933 shares in the last quarter. Bank of Montreal Can grew its position in shares of Arrowhead Pharmaceuticals by 13.3% during the 4th quarter. Bank of Montreal Can now owns 15,018 shares of the biotechnology company's stock valued at $282,000 after purchasing an additional 1,759 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $651,000. Summit Investment Advisors Inc. grew its position in shares of Arrowhead Pharmaceuticals by 2.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock valued at $714,000 after purchasing an additional 803 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Arrowhead Pharmaceuticals by 13.0% during the 4th quarter. Barclays PLC now owns 312,560 shares of the biotechnology company's stock valued at $5,876,000 after purchasing an additional 35,950 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.